Literature DB >> 30663774

Eligibility for CAR T-cell therapy: An analysis of selection criteria and survival outcomes in chemorefractory DLBCL.

Stephen D Smith1, Prathima Reddy2, Alexandra Sokolova1, Victor A Chow1, Ryan C Lynch1, Mazyar A Shadman1, Brian G Till1, Andrei R Shustov1, Edus H Warren1, Chaitra S Ujjani1, Manoj P Menon1, Yolanda D Tseng3, Ajay K Gopal1.   

Abstract

Entities:  

Year:  2019        PMID： 30663774     DOI： 10.1002/ajh.25411

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  6 in total

Review 1.  Cellular Immunotherapy for Refractory Diffuse Large B Cell Lymphoma in the Chimeric Antigen Receptor-Engineered T Cell Era: Still a Role for Allogeneic Transplantation?

Authors:  Peter Dreger; Timothy S Fenske; Silvia Montoto; Marcelo C Pasquini; Anna Sureda; Mehdi Hamadani
Journal:  Biol Blood Marrow Transplant       Date:  2020-01-07       Impact factor: 5.742

Review 2.  CAR T-Cell Therapy in the Older Person: Indications and Risks.

Authors:  Geoffrey Shouse; Alexey V Danilov; Andy Artz
Journal:  Curr Oncol Rep       Date:  2022-04-14       Impact factor: 5.945

Review 3.  CAR-T Cells: Future Perspectives.

Authors:  Sarah Charrot; Simon Hallam
Journal:  Hemasphere       Date:  2019-03-19

Review 4.  Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives.

Authors:  Roman P Labbé; Sandrine Vessillier; Qasim A Rafiq
Journal:  Viruses       Date:  2021-08-02       Impact factor: 5.048

Review 5.  The Application of CAR-T Cells in Haematological Malignancies.

Authors:  Katarzyna Skorka; Katarzyna Ostapinska; Aneta Malesa; Krzysztof Giannopoulos
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2020-11-06       Impact factor: 4.291

6.  Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells.

Authors:  Anna Dalla Pietà; Elisa Cappuzzello; Roberta Sommaggio; Antonio Rosato; Pierangela Palmerini; Annavera Ventura; Andrea Visentin; Giuseppe Astori; Katia Chieregato; Valentina Mozzo; Omar Perbellini; Maria Chiara Tisi; Livio Trentin; Carlo Visco; Marco Ruggeri
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.